Anacor Pharmaceuticals Inc., of Palo Alto, Calif., said a peer-reviewed article describing the recent progress of boron-based compounds in medicine and the properties of these compounds that support their development for the treatment of various skin disorders will be published in the Journal of Clinical and Aesthetic Dermatology. Read More
Zogenix Inc., of San Diego, published phase III results showing that Zohydro ER (hydrocodone bitartrate) extended-release capsules was well tolerated and effective for the treatment of moderate to severe chronic low back pain. Read More
Vanda Pharmaceuticals Inc., of Washington, reported that their total revenues for the full year 2013 were $33.9 million compared to $32.7 million for 2012. Read More
Carrot juice has long been celebrated for its healthy vitamin and mineral content, but for Gaucher disease patients, a genetically engineered form of the drink could have life-saving properties. Read More
Though winter storm Pax put the freeze on air and ground traffic in the Northeast U.S. after ravaging the South, biotech funders seemed to feel little of the chill, with PTC Therapeutics Inc. and Macrogenics Inc. pricing public offerings for $109.7 million and $109.5 million, respectively. Read More
Shares in Karo Bio AB dropped 13 percent Thursday on news that the company was raising SEK84.7 million (US$13.1 million) in a heavily discounted share issue. Read More
Investors raised their wallets Thursday for Concert Pharmaceuticals Inc., which priced its initial public offering (IPO) at $14 – the top of its proposed range – after previously upsizing from 5 million to 6 million shares. The stock swelled above the offering price as trading commenced on the Nasdaq Global Market under the ticker “CNCE,” hitting $16.24 before settling back to close at $14.18 for a gain of 18 cents on the day. Read More
Teva Pharmaceutical Industries Ltd., of Jerusalem, said the FDA granted full approval of Synribo (omacetaxine mepesuccinate) for injection following the drug’s accelerated approval in October 2012, which was conditioned on the provision of additional clinical trial data to fulfill post-marketing requirements. Read More
